We show that normally germline‑restricted HORMAD1 induces aneuploidy in TNBC by disrupting Aurora B/INCENP and weakening spindle assembly checkpoint. This creates sensitivity to MPS1, Aurora B, and BUB1 inhibitors. Work @icr.ac.uk funded by @breastcancernow.bsky.social and published rdcu.be/e7Som
Our new study is out in Nature Communications.
Using TNBC organoid mouse models, we show that necroptosis in both tumour and stromal compartments cooperatively drives effective responses to immunogenic cell death–based immunotherapy.
🔗 www.nature.com/articles/s41...
Has anybody a serious argument against funding this.
Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social
Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org
Yes ! Drive and intelligence more important than experience.
We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...
A photo of Jim O'Neil getting sworn in by RFK Jr. You can see a close-up of his tie.
The same tie on Otaa's website. The site shows the tie is made from 100% microfiber.
The label for Otaa'a ties. It says "Designed in Australia."
The back of the label. It says "100% Microfiber. Hand Made Made in China"
RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.
Thrilled to share our latest work, just published in @nature.com ⬇
www.nature.com/articles/s41...
We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors.
🧵 (1/8)
our bit funded by @breastcancernow.bsky.social @cancerresearchuk.org and carried out @icr.ac.uk
With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
Academic writing is a craft. ✍️
You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well.
Your writing is the first thing people see before they meet you. Make it count.
This is fascinating:
Watch this space: Stephen is going to do great things with this funding from the Lister Institute.
Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️
🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk
#bcsm #ai #CancerResearch
🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR
Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open!
humantechnopole.it/en/trainings...
youtu.be/x2erCuovGvc
#EuroDepMap
Loving “pertomics”. Going to push the term “buffomics” too.
We're looking for a Scientific Operations Project Manager
to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
pubmed.ncbi.nlm.nih.gov/28535155/
The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer
www.nature.com/articles/s41...
✅Sac-TMT significantly improved progression-free survival PFS
this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.
Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...
And Elvis 75 the best single never released
PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻
A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet
Brainchild of the amazing #GeneKoh
(Sir Jeffrey Cheah ECR)
Tweetorial below!! 👇
1/n
www.nature.com/articles/s41...
www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.
A must for all DNA repair aficionados!
Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱
✔️ Confirmed top speakers
✔️ Ample opportunities for talks & posters
Don’t miss it: dnarepairmeeting-egmond2026.com
We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.
